COLL - コレギウム・ファ―マシュ―ティカル (Collegium Pharmaceutical Inc.) コレギウム・ファ―マシュ―ティカル

 COLLのチャート


 COLLの企業情報

symbol COLL
会社名 Collegium Pharmaceuticals Inc (コレギウム・ファ―マシュ―ティカル)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 コレギウム・ファーマシューティカル(Collegium Pharmaceutical Inc.)は特殊医薬品会社である。同社は、慢性疼痛及びその他疾患の治療用「DETERx」プラットフォーム技術を組み込んだ乱用防止製品の開発・製品化を行う。同社の製品はXtampza ERとONSOLISを含む。DETERxプラットフォームは、鎮痛、咀嚼、加熱および注射を含む一般的な乱用と改ざんの方法に対して保護しながら、徐放性ドラッグデリバリーを提供する。Xtampza ERは、一般的な乱用と偶発的な誤用を受けた後、徐放性薬物放出プロファイルを維持しながら、適切な疼痛管理を提供するように設計された。ONSOLISは、永続的な癌の痛みのために既にオピオイド療法を受けて耐性がある18歳以上のがん患者(BTPc)における突破痛の管理を目的とする経粘膜即時放出フェンタニル(TIRF)フィルムである。   コレギウム・ファ―マシュ―ティカルは米国の製薬会社。慢性疼痛および他の疾患の治療用に開発された特許取得済みプラットフォ―ム技術「DETERx」を組み込んだ、次世代の医薬品の開発、製品化を手掛ける。開発中の医薬品に「Xtampza ER」や「Xtampza」がある。   Collegium Pharmaceutical Inc. is a specialty pharmaceutical company committed to being the leader in responsible pain management. Collegium's headquarters are located in Stoughton, Massachusetts.
本社所在地 780 Dedham Street Suite 800 Canton MA 02021 USA
代表者氏名 Michael Thomas Heffernan マイケル・トーマス・ヘファナン
代表者役職名 Chairman of the Board President 取締役会長会長
電話番号 +1 781-713-3699
設立年月日 37347
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 250人
url www.collegiumpharma.com
nasdaq_url https://www.nasdaq.com/symbol/coll
adr_tso
EBITDA EBITDA(百万ドル) 11.26000
終値(lastsale) 16.98
時価総額(marketcap) 564104533.92
時価総額 時価総額(百万ドル) 571.41330
売上高 売上高(百万ドル) 159.55400
企業価値(EV) 企業価値(EV)(百万ドル) 449.16630
当期純利益 当期純利益(百万ドル) -62.37800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Collegium Pharmaceutical Inc revenues increased from $5.7M to $136.8M. Net loss decreased 28% to $31.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Interest Income increase from $235K to $646K (income) Research and Development decrease of 1% to $3.8M (expense).

 COLLのテクニカル分析


 COLLのニュース

   Collegium Pharmaceutical Inc (COLL) falls -1.8060% for June 17 - Equities News  2021/06/22 11:12:27 Equities
Collegium Pharmaceutical Inc (COLL) falls -1.8060% for June 17 Equities.com
   Collegium Announces Publication of Real-World Data in Journal of Pain Research  2021/06/16 20:01:00 Benzinga
STOUGHTON, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ: COLL ), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced a publication titled, "Nonmedical Use of Xtampza ® ER and Other Oxycodone Medications in Adults Evaluated for Substance Abuse Treatment: Real-world Data from the Addiction Severity Index Multimedia Version (ASI-MV ® )," was published in the peer-reviewed medical journal, Journal of Pain Research . "An important part of our commitment to responsible pain management includes ongoing surveillance of real-world data assessing the incidence of abuse, misuse and diversion related to our product portfolio," said Richard Malamut, M.D., Executive Vice President and Chief Medical Officer of Collegium. "We will continue to support the analysis and publication of real-world data as it becomes available. We believe it is important for the medical and scientific communities to have access to these data to inform treatment decisions when prescribing effective analgesic therapy to treat people suffering from pain." While the analysis reported in this publication contributes to an understanding of the relative rates of nonmedical use of various opioid products, nothing in the findings should be construed as suggesting that Xtampza ER (oxycodone) extended-release capsules, does not have a high potential for addiction, abuse, or misuse.
   Needham Releases a Buy Rating on Collegium Pharmaceutical (COLL)  2021/05/28 13:15:12 Smarter Analyst
Needham analyst Serge Belanger assigned a Buy rating to Collegium Pharmaceutical (COLL) today and set a price target of $34.00. The post Needham Releases a Buy Rating on Collegium Pharmaceutical (COLL) appeared first on Smarter Analyst .
   Collegium to Participate in Upcoming Investor Conference - May 20, 2021  2021/05/20 00:00:00 BioSpace
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company committed to being the leader in responsible pain management, announced that management will participate in the following investor conference
   Needham Gives a Buy Rating to Collegium Pharmaceutical (COLL)  2021/05/14 13:55:31 Smarter Analyst
In a report released today, Serge Belanger from Needham assigned a Buy rating to Collegium Pharmaceutical (COLL), with a price target of $34.00. The post Needham Gives a Buy Rating to Collegium Pharmaceutical (COLL) appeared first on Smarter Analyst .
   Collegium Announces Publication of Real-World Data in Journal of Pain Research  2021/06/16 20:01:00 Benzinga
STOUGHTON, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ: COLL ), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced a publication titled, "Nonmedical Use of Xtampza ® ER and Other Oxycodone Medications in Adults Evaluated for Substance Abuse Treatment: Real-world Data from the Addiction Severity Index Multimedia Version (ASI-MV ® )," was published in the peer-reviewed medical journal, Journal of Pain Research . "An important part of our commitment to responsible pain management includes ongoing surveillance of real-world data assessing the incidence of abuse, misuse and diversion related to our product portfolio," said Richard Malamut, M.D., Executive Vice President and Chief Medical Officer of Collegium. "We will continue to support the analysis and publication of real-world data as it becomes available. We believe it is important for the medical and scientific communities to have access to these data to inform treatment decisions when prescribing effective analgesic therapy to treat people suffering from pain." While the analysis reported in this publication contributes to an understanding of the relative rates of nonmedical use of various opioid products, nothing in the findings should be construed as suggesting that Xtampza ER (oxycodone) extended-release capsules, does not have a high potential for addiction, abuse, or misuse.
   Needham Releases a Buy Rating on Collegium Pharmaceutical (COLL)  2021/05/28 13:15:12 Smarter Analyst
Needham analyst Serge Belanger assigned a Buy rating to Collegium Pharmaceutical (COLL) today and set a price target of $34.00. The post Needham Releases a Buy Rating on Collegium Pharmaceutical (COLL) appeared first on Smarter Analyst .
   Collegium to Participate in Upcoming Investor Conference - May 20, 2021  2021/05/20 00:00:00 BioSpace
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company committed to being the leader in responsible pain management, announced that management will participate in the following investor conference
   Needham Gives a Buy Rating to Collegium Pharmaceutical (COLL)  2021/05/14 13:55:31 Smarter Analyst
In a report released today, Serge Belanger from Needham assigned a Buy rating to Collegium Pharmaceutical (COLL), with a price target of $34.00. The post Needham Gives a Buy Rating to Collegium Pharmaceutical (COLL) appeared first on Smarter Analyst .
   Needham Releases a Buy Rating on Collegium Pharmaceutical (COLL)  2021/05/28 13:15:12 Smarter Analyst
Needham analyst Serge Belanger assigned a Buy rating to Collegium Pharmaceutical (COLL) today and set a price target of $34.00. The post Needham Releases a Buy Rating on Collegium Pharmaceutical (COLL) appeared first on Smarter Analyst .
   Collegium to Participate in Upcoming Investor Conference - May 20, 2021  2021/05/20 00:00:00 BioSpace
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company committed to being the leader in responsible pain management, announced that management will participate in the following investor conference
   Needham Gives a Buy Rating to Collegium Pharmaceutical (COLL)  2021/05/14 13:55:31 Smarter Analyst
In a report released today, Serge Belanger from Needham assigned a Buy rating to Collegium Pharmaceutical (COLL), with a price target of $34.00. The post Needham Gives a Buy Rating to Collegium Pharmaceutical (COLL) appeared first on Smarter Analyst .

 関連キーワード  (医薬品 米国株 コレギウム・ファ―マシュ―ティカル COLL Collegium Pharmaceutical Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)